Island Pharma accelerates Galidesivir development through major US government partnership. The ASX-listed biotech has signed a three-year CRADA with USAMRIID and The Geneva Foundation to advance its antiviral candidate for Marburg Virus Disease under the FDA Animal Rule pathway. The collaboration focuses on non-human primate studies essential for New Drug Application approval. Island Pharma secured nine million dollars earlier this year to fund the two-stage development program. The partnership leverages established biodefense infrastructure and approximately 383 million USD in annual research funding managed by The Geneva Foundation. Success could lead to NDA submission, US government procurement opportunities, and a valuable Priority Review Voucher, significantly de-risking the program with a clear regulatory roadmap now confirmed by the FDA.